Strategies and methods of nanocrystal technology for targeting drug delivery
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Ma Y, Cong Z, Gao P, Wang Y (2023) Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate. Eur J Pharm Sci 185:10642510.1016/j.ejps.2023.106425 ↗
2. Elbaz NM, Tatham LM, Owen A, Rannard S, McDonald TO (2023) Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery. Food Hydrocoll 144:10890810.1016/j.foodhyd.2023.108908 ↗
3. Wang B, Wang X, Zhu Y, Yin T, Gou J, Wang Y, He H, Zhang Y, Tang X (2022) Characterization of nimodipine amorphous nanopowder prepared by quenching cooling combined with wet milling and spray drying. Int J Pharm 628:122332
4. Liu Y, Ma Y, Xue L, Guan W, Wang Y (2023) Pulmonary multidrug codelivery of curcumin nanosuspensions and ciprofloxacin with N-acetylcysteine for lung infection therapy. J Drug Deliv Sci Technol 84:10447410.1016/j.jddst.2023.104474 ↗
5. Mule S, Khairnar P, Shukla R (2022) Recent advances in nanocrystals heralding greater potential in brain delivery. Part Part Syst Charact 39:220008710.1002/ppsc.202200087 ↗
6. Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK (2014) Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release 183:51–6610.1016/j.jconrel.2014.03.030 ↗
7. Liu P, Du H, Chen Y, Wang H, Mao J, Zhang L, Tao J, Zhu J (2020) Polymer microneedles with interconnected porous structures via a phase inversion route for transdermal medical applications. J Mater Chem B 8:2032–203910.1039/C9TB02837D ↗
8. Shariare MH, Sharmin S, Jahan I, Reza HM, Mohsin K (2018) The impact of process parameters on carrier free paracetamol nanosuspension prepared using different stabilizers by antisolvent precipitation method. J Drug Deliv Sci Technol 43:122–12810.1016/j.jddst.2017.10.001 ↗
9. Yu S, Wang S, Zou P, Chai G, Lin Y-W, Velkov T, Li J, Pan W, Zhou QT (2020) Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. Int J Pharm 575:11891510.1016/j.ijpharm.2019.118915 ↗
10. Ahmad S, Khan I, Pandit J, Emad NA, Bano S, Dar KI, Rizvi MMA, Ansari MD, Aqil M, Sultana Y (2022) Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment. Int J Biol Macromol 221:435–44510.1016/j.ijbiomac.2022.08.210 ↗
11. Liang Y, Fu X, Du C, Xia H, Lai Y, Sun YJAC (2020) Enzyme/pH-triggered anticancer drug delivery of chondroitin sulfate modified doxorubicin nanocrystal. Nanomed Biotechnol 48:1114–1124
12. Bai M, Yang M, Gong J, Xu H, Wei Z (2021) Progress and principle of drug nanocrystals for tumor targeted delivery. AAPS PharmSciTech 23:4110.1208/s12249-021-02200-w ↗
13. Davodabadi F, Sajjadi SF, Sarhadi M, Mirghasemi S, Nadali Hezaveh M, Khosravi S, Kamali Andani M, Cordani M, Basiri M, Ghavami S (2023) Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol 958:17601310.1016/j.ejphar.2023.176013 ↗
14. Wang J, Muhammad N, Li T, Wang H, Liu Y, Liu B, Zhan H (2020) Hyaluronic acid-coated camptothecin nanocrystals for targeted drug delivery to enhance anticancer efficacy. Mol Pharm 17:2411–242510.1021/acs.molpharmaceut.0c00161 ↗
15. Gan M, Zhang W, Wei S, Dang H (2017) The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of SN-38 NPs. Artif Cells Nanomed Biotechnol 45:389–39710.3109/21691401.2016.1167700 ↗
16. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–2510.1016/j.addr.2013.11.009 ↗
17. Kim HJ, Lim YG, Song YJ, Park K (2023) Folate receptor-targetable and tumor microenvironment-responsive manganese dioxide-based nano-photosensitizer for enhancing hypoxia alleviation-triggered phototherapeutic effects. J Ind Eng Chem 119:428–43810.1016/j.jiec.2022.11.065 ↗
18. Kim M, Kim S-B, Kim J, Kim K-S, Kim D-E (2023) Co-delivery of curcumin and PTTG1 siRNA by galactose receptor-targeted liposomes for enhanced anti-tumor effects in hepatocellular carcinoma. J Drug Deliv Sci Technol 86:10469210.1016/j.jddst.2023.104692 ↗
19. Alkilany AM, Zhu L, Weller H, Mews A, Parak WJ, Barz M, Feliu N (2019) Ligand density on nanoparticles: a parameter with critical impact on nanomedicine. Adv Drug Deliv Rev 143:22–3610.1016/j.addr.2019.05.010 ↗
20. Wang W, Zhang M, Zhang Q, Mohammadniaei M, Shen J, Sun Y (2022) Brain-targeted antigen-generating nanoparticles improve glioblastoma prognosis. J Control Release 352:399–41010.1016/j.jconrel.2022.10.037 ↗
21. Wang X, Ye L, He W, Teng C, Sun S, Lu H, Li S, Lv L, Cao X, Yin H, Lv W, Xin H (2022) In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. J Control Release 345:786–79710.1016/j.jconrel.2022.03.050 ↗
22. Siegelin MD, Schneider E, Westhoff M-A, Wirtz CR, Karpel-Massler G (2021) Current state and future perspective of drug repurposing in malignant glioma. Semin Cancer Biol, Elsevier 68:92–10410.1016/j.semcancer.2019.10.018 ↗
23. Belhadj Z, Ying M, Cao X, Hu X, Zhan C, Wei X, Gao J, Wang X, Yan Z, Lu W (2017) Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. J Control Release 255:132–14110.1016/j.jconrel.2017.04.006 ↗
24. Zhu S, Sun F, Zhao P, Liang G, Sun X, Zeng L, Huang Y (2022) Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression. Int J Pharm 619:121709
25. Wei X, Gao J, Zhan C, Xie C, Chai Z, Ran D, Ying M, Zheng P, Lu W (2015) Liposome-based glioma targeted drug delivery enabled by stable peptide ligands. J Control Release 218:13–2110.1016/j.jconrel.2015.09.059 ↗
26. Lei X, Hu X, Zhang T, Zhang J, Wu C, Hong W, Jiang Y, Wang Q, Xie Y, Zhao Y (2020) HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression. Cell Signal 72:10963110.1016/j.cellsig.2020.109631 ↗
27. Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y, Wei Z, Wang L, Kong L, Sun H (2017) Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol 12:692–70010.1038/nnano.2017.54 ↗
28. Song Q, Yin Y, Shang L, Wu T, Zhang D, Kong M, Zhao Y, He Y, Tan S, Guo Y (2017) Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy. Nano Lett 17:6366–637510.1021/acs.nanolett.7b03186 ↗
29. Wang P, Wang Y, Li P, Chen C, Ma S, Zhao L, He H, Yin T, Zhang Y, Tang X, Gou J (2023) Oral delivery of polyester nanoparticles for brain-targeting: challenges and opportunities. Chin Chem Lett 34:10769110.1016/j.cclet.2022.07.034 ↗
30. Correia AC, Monteiro AR, Silva R, Moreira JN, Sousa Lobo JM, Silva AC (2022) Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders. Adv Drug Deliv Rev 189:11448510.1016/j.addr.2022.114485 ↗
31. Li J, Chai Z, Lu J, Xie C, Ran D, Wang S, Zhou J, Lu W (2020) ɑvβ3-targeted liposomal drug delivery system with attenuated immunogenicity enabled by linear pentapeptide for glioma therapy. J Control Release 322:542–55410.1016/j.jconrel.2020.04.009 ↗
32. Sorrell TC, Juillard P-G, Djordjevic JT, Kaufman-Francis K, Dietmann A, Milonig A, Combes V, Grau GER (2016) Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between Cryptococcus neoformans var. grubii strain H99 and Cryptococcus gattii strain R265. Microbes Infect 18:57–6710.1016/j.micinf.2015.08.017 ↗
33. Arora S, Kanekiyo T, Singh J (2022) Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer’s disease pathology in transgenic mouse model. Int J Biol Macromol 208:901–91110.1016/j.ijbiomac.2022.03.203 ↗
34. Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML (2017) Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye – Part I - Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm 110:70–7510.1016/j.ejpb.2016.10.009 ↗
35. Pina Costa C, Nižić Nodilo L, Silva R, Martins E, Zadravec D, Kalogjera L, Nuno Moreira J, Manuel Sousa Lobo J, Hafner A, Catarina Silva A (2023) In situ hydrogel containing diazepam-loaded nanostructured lipid carriers (DZP-NLC) for nose-to-brain delivery: development, characterization and deposition studies in a 3D-printed human nasal cavity model. Int J Pharm 644:12334510.1016/j.ijpharm.2023.123345 ↗
36. Pardridge WM (2020) Treatment of Alzheimer’s disease and blood-brain barrier drug delivery. Pharmaceuticals (Basel) 13(11):39410.3390/ph13110394 ↗
37. Aditya NP, Macedo AS, Doktorovova S, Souto EB, Kim S, Chang P-S, Ko S (2014) Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT Food Sci Technol 59:115–12110.1016/j.lwt.2014.04.058 ↗
38. Dolatabadi S, Karimi M, Nasirizadeh S, Hatamipour M, Golmohammadzadeh S, Jaafari MR (2021) Preparation, characterization and in vivo pharmacokinetic evaluation of curcuminoids-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). J Drug Deliv Sci Technol 62:10235210.1016/j.jddst.2021.102352 ↗
39. Sakellari GI, Zafeiri I, Batchelor H, Spyropoulos F (2021) Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active. Food Hydrocoll Health 1:10002410.1016/j.fhfh.2021.100024 ↗
40. Subhash Hinge N, Kathuria H, Monohar Pandey M (2023) Rivastigmine-DHA ion-pair complex improved loading in hybrid nanoparticles for better amyloid inhibition and nose-to-brain targeting in Alzheimer’s. Eur J Pharm Biopharm 190:131–14910.1016/j.ejpb.2023.06.007 ↗
41. Mishra A, Kumar R, Mishra J, Dutta K, Ahlawat P, Kumar A, Dhanasekaran S, Gupta AK, Sinha S, Bishi DK, Gupta PK, Nayak S (2023) Strategies facilitating the permeation of nanoparticles through blood-brain barrier: an insight towards the development of brain-targeted drug delivery system. J Drug Deliv Sci Technol 86:10469410.1016/j.jddst.2023.104694 ↗
42. Fu T-T, Cong Z-Q, Zhao Y, Chen W-Y, Liu C-Y, Zheng Y, Yang F-F, Liao Y-H (2019) Fluticasone propionate nanosuspensions for sustained nebulization delivery: an in vitro and in vivo evaluation. Int J Pharm 572:11883910.1016/j.ijpharm.2019.118839 ↗
43. Fu T-T, Zhao Y, Yang F-F, Wen H, Liu C-Y, Liao Y-H (2018) Ciclesonide and budesonide suspensions for nebulization delivery: an in vivo inhalation biopharmaceutics investigation. Int J Pharm 549:21–3010.1016/j.ijpharm.2018.07.048 ↗
44. Makled S, Nafee N, Boraie N (2017) Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. Int J Pharm 517:312–32110.1016/j.ijpharm.2016.12.026 ↗
45. Wu J, Zhai T, Sun J, Yu Q, Feng Y, Li R, Wang H, Ouyang Q, Yang T, Zhan Q, Deng L, Qin M, Wang F (2022) Mucus-permeable polymyxin B-hyaluronic acid/poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections. J Colloid Interface Sci 624:307–31910.1016/j.jcis.2022.05.121 ↗
46. Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E (2019) A breath of fresh air in the fog of antimicrobial resistance: inhaled polymyxins for Gram-negative pneumonia. Antibiotics (Basel) 8:2710.3390/antibiotics8010027 ↗
47. Şen Karaman D, Ercan UK, Bakay E, Topaloğlu N, Rosenholm JM (2020) Evolving technologies and strategies for combating antibacterial resistance in the advent of the postantibiotic era. Adv Funct Mater 30:190878310.1002/adfm.201908783 ↗
48. Douafer H, Andrieu V, Wafo E, Brunel JM (2020) Characterization of a new aerosol antibiotic/adjuvant combination for the treatment of P. aeruginosa lung infections. Int J Pharm 586:11954810.1016/j.ijpharm.2020.119548 ↗
49. Huang T, Qian Y, Fu X, Huang S, Li Y, Zhou C (2020) De novo design of triblock amphiphilic short antimicrobial peptides. ACS Appl Polym Mater 2:3988–399210.1021/acsapm.0c00640 ↗
50. Bao C, Liu B, Li B, Chai J, Zhang L, Jiao L, Li D, Yu Z, Ren F, Shi X (2020) Enhanced transport of shape and rigidity-tuned α-lactalbumin nanotubes across intestinal mucus and cellular barriers. Nano Lett 20:1352–136110.1021/acs.nanolett.9b04841 ↗
51. Kobayashi T, Chanmee T, Itano N (2020) Hyaluronan: metabolism and function. Biomolecules 10(11):152510.3390/biom10111525 ↗
52. Jeannot V, Gauche C, Mazzaferro S, Couvet M, Vanwonterghem L, Henry M, Didier C, Vollaire J, Josserand V, Coll J-L (2018) Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. J Control Release 275:117–12810.1016/j.jconrel.2018.02.024 ↗
53. Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA (2019) Clinical Applications of Hyaluronidase 1148:255–27710.1007/978-981-13-7709-9_12 ↗
54. Ma X, Tan YT, Yang Y, Gao J, Li HL, Zheng W, Lan Q, Rothman N, Shu XO, Xiang YB (2018) Pre-diagnostic urinary 15–F2t-isoprostane level and liver cancer risk: results from the Shanghai Women’s and Men’s Health Studies. Int J Cancer 143:1896–190310.1002/ijc.31591 ↗
55. Yang W, Zhang Y, Wang J, Li H, Yang H (2022) Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier. Int J Biol Macromol 216:789–79810.1016/j.ijbiomac.2022.07.182 ↗
56. Stecanella LA, Bitencourt AP, Vaz GR, Quarta E, Silva Júnior JO, Rossi A (2021) Glycyrrhizic acid and its hydrolyzed metabolite 18β-glycyrrhetinic acid as specific ligands for targeting nanosystems in the treatment of liver cancer. Pharmaceutics 13:179210.3390/pharmaceutics13111792 ↗
57. Wu F, Xue H, Li X, Diao W, Jiang B, Wang W, Yu W, Bai J, Wang Y, Lian BJB (2020) Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro. Pharmacotherapy 131:110682
58. Kim J, Lee S, Na K (2020) Glycyrrhetinic acid-modified silicon phthalocyanine for liver cancer-targeted photodynamic therapy. Biomacromolecules 22:811–82210.1021/acs.biomac.0c01550 ↗
59. Ganguly BN, Verma V, Chatterjee D, Satpati B, Debnath S, Saha P (2016) Study of gallium oxide nanoparticles conjugated with β-cyclodextrin: an application to combat cancer. ACS Appl Mater Interfaces 8:17127–1713710.1021/acsami.6b04807 ↗
60. Prabha G, Raj VJB (2016) Formation and characterization of β-cyclodextrin (β-CD)–polyethyleneglycol (PEG)–polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-Fluorouracil drug. Pharmacotherapy 80:173–18210.1016/j.biopha.2016.03.015 ↗
61. Soundararajan D, Ramana LN, Shankaran P, Krishnan UM (2022) Nanoparticle-based strategies to target HIV-infected cells. Colloids Surf B Biointerfaces 213:11240510.1016/j.colsurfb.2022.112405 ↗
62. Sailaja I, Baghel MK, Shaker IA (2021) Nanotechnology based drug delivery for HIV-AIDS treatment. In: AIDS updates-recent advances and new perspectives. IntechOpen. https://doi.org/10.5772/intechopen.9773610.5772/intechopen.97736 ↗
63. Cunha RF, Simões S, Carvalheiro M, Pereira JMA, Costa Q, Ascenso A (2021) Novel antiretroviral therapeutic strategies for HIV. Molecules 26:530510.3390/molecules26175305 ↗
64. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16:1–3310.1186/s12951-018-0392-8 ↗
65. Docquier J-D, Cusi MG (2014) Editorial overview: Anti-infectives: towards novel antiviral and antibacterial drugs? Current approaches to address a growing medical need. Curr Opin Pharmacol 18:iv–vi10.1016/j.coph.2014.10.004 ↗
66. Mehrotra S, Salwa, Bg PK, Bhaskaran NA, Srinivas Reddy J, Kumar L (2023) Nose-to-brain delivery of antiretroviral drug loaded lipidic nanocarriers to purge HIV reservoirs in CNS: a safer approach. J Drug Deliv Sci Technol 87:10483310.1016/j.jddst.2023.104833 ↗
67. Faizal NDFM, Ramli NA, Rani NNIM, Shaibie NA, Yadav A, Poonsawas P, Sharma SK, Amin MCIM (2023) Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants. Asian J Pharm Sci 18:10085510.1016/j.ajps.2023.100855 ↗
68. Wang J, Guo N, Hou W (2023) Antiviral drug carriers for human immunodeficiency virus. Nano Trends 4:10002710.1016/j.nwnano.2023.100027 ↗
69. Xu J, Song M, Fang Z, Zheng L, Huang X, Liu K (2022) Applications and challenges of ultra-small particle size nanoparticles in tumor therapy. J Control Release 353:699–71210.1016/j.jconrel.2022.12.028 ↗
70. Ding J, Chen J, Gao L, Jiang Z, Zhang Y, Li M, Xiao Q, Lee SS, Chen X (2019) Engineered nanomedicines with enhanced tumor penetration. Nano Today 29:10080010.1016/j.nantod.2019.100800 ↗
71. Fang J, Islam W, Maeda H (2020) Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev 157:142–16010.1016/j.addr.2020.06.005 ↗
72. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH (2021) Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics 13:118310.3390/pharmaceutics13081183 ↗
73. Wadhwa A, Bobak TR, Bohrmann L, Geczy R, Sekar S, Sathyanarayanan G, Kutter JP, Franzyk H, Foged C, Saatchi K, Häfeli UO (2023) Pulmonary delivery of siRNA-loaded lipid-polymer hybrid nanoparticles: effect of nanoparticle size. OpenNano 13:10018010.1016/j.onano.2023.100180 ↗
74. Mok ZH (2023) The effect of particle size on drug bioavailability in various parts of the body. Pharm Sci Adv 2:10003110.1016/j.pscia.2023.100031 ↗
75. Ikeda-Imafuku M, Wang LL-W, Rodrigues D, Shaha S, Zhao Z, Mitragotri S (2022) Strategies to improve the EPR effect: a mechanistic perspective and clinical translation. J Control Release 345:512–53610.1016/j.jconrel.2022.03.043 ↗
76. Rakhilin N, Yang B, Spilker ME, Manzuk LK, Montgomery MK, Shin E, Prashad N, Hwang J, Song Y, Loganzo F, Giddabasappa A, Ram S (2023) Volumetric imaging of optically cleared and fluorescently labeled animal tissue (VIOLA) for quantifying the 3D biodistribution of nanoparticles at cellular resolution in tumor tissue. J Control Release 354:244–25910.1016/j.jconrel.2022.12.060 ↗
77. Togami K, Ishizawa K, Yasuda M, Tada H, Chono S (2023) Development of visualization and analysis methods for evaluating intratumoral nanoparticle kinetics for tumor-targeted drug delivery using Förster resonance energy transfer in vivo live imaging and tissue clearing techniques. J Pharm Biomed Anal 223:11512710.1016/j.jpba.2022.115127 ↗
78. Etter EL, Mei K-C, Nguyen J (2021) Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems. Adv Drug Deliv Rev 179:11399410.1016/j.addr.2021.113994 ↗
79. Bai S, Zhang Y, Li D, Shi X, Lin G, Liu G (2021) Gain an advantage from both sides: smart size-shrinkable drug delivery nanosystems for high accumulation and deep penetration. Nano Today 36:10103810.1016/j.nantod.2020.101038 ↗
80. Hasanzadeh Kafshgari M, Harding FJ, Voelcker NH (2015) Insights into cellular uptake of nanoparticles. Curr Drug Deliv 12:63–7710.2174/1567201811666140821110631 ↗
81. Dewhirst MW, Secomb TW (2017) Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer 17:738–75010.1038/nrc.2017.93 ↗
82. Puri V, Kaur VP, Singh A, Singh C (2022) Recent advances on drug delivery applications of mucopenetrative/mucoadhesive particles: a review. J Drug Deliv Sci Technol 75:10371210.1016/j.jddst.2022.103712 ↗
83. Chater PI, Wilcox MD, Pearson JP (2018) Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems. Adv Drug Deliv Rev 124:184–19210.1016/j.addr.2017.12.006 ↗
84. Nguyen TT, Park JH (2018) Human studies with microneedles for evaluation of their efficacy and safety. Expert Opin Drug Deliv 15:235–24510.1080/17425247.2018.1410138 ↗
85. Muresan P, McCrorie P, Smith F, Vasey C, Taresco V, Scurr DJ, Kern S, Smith S, Gershkovich P, Rahman R, Marlow M (2022) Development of nanoparticle loaded microneedles for drug delivery to a brain tumour resection site. Eur J Pharm Biopharm 182:53–6110.1016/j.ejpb.2022.11.016 ↗
86. Pitorre M, Gazaille C, Pham LTT, Frankova K, Béjaud J, Lautram N, Riou J, Perrot R, Geneviève F, Moal V, Benoit J-P, Bastiat G (2021) Polymer-free hydrogel made of lipid nanocapsules, as a local drug delivery platform. Mater Sci Eng: C 126:11218810.1016/j.msec.2021.112188 ↗
87. Ashby LS, Smith KA, Stea B (2016) Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol 14:1–1510.1186/s12957-016-0975-5 ↗
88. Bastiancich C, Danhier P, Préat V, Danhier F (2016) Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. J Control Release 243:29–4210.1016/j.jconrel.2016.09.034 ↗
89. Dugam S, Tade R, Dhole R, Nangare S (2021) Emerging era of microneedle array for pharmaceutical and biomedical applications: recent advances and toxicological perspectives. Future J Pharm Sci 7:1–2610.1186/s43094-020-00150-x ↗
90. Tekko IA, Permana AD, Vora L, Hatahet T, McCarthy HO, Donnelly RF (2020) Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: potential for enhanced treatment of psoriasis. Eur J Pharm Sci 152:10546910.1016/j.ejps.2020.105469 ↗
91. Liu Y, Zhang Z, Wang C, Xie X, Ma Y, Wang Y (2023) Biodegradable and dissolvable resveratrol nanocrystals non-silicon microneedles for transdermal drug delivery. J Drug Deliv Sci Technol 86:10465310.1016/j.jddst.2023.104653 ↗
92. Wang Q, Yang X, Gu X, Wei F, Cao W, ZhengL, Li Y, Ma T, Wu C, Wang Q (2022) Celecoxib nanocrystal-loaded dissolving microneedles with highly efficient for osteoarthritis treatment. Int J Pharm 625:12210810.1016/j.ijpharm.2022.122108 ↗
93. Wei S, Xie J, Luo Y, Ma Y, Tang S, Yue P, Yang M (2018) Hyaluronic acid based nanocrystals hydrogels for enhanced topical delivery of drug: a case study. Carbohyd Polym 202:64–7110.1016/j.carbpol.2018.08.112 ↗
94. Fan R, Sun W, Zhang T, Wang R, Tian Y, Zhang H, Li J, Zheng A, Song S (2022) Paclitaxel-nanocrystals-loaded network thermosensitive hydrogel for localised postsurgical recurrent of breast cancer after surgical resection. Biomed Pharmacother 150:122108
95. Wei S, Xie J, Luo Y, Ma Y, Tang S, Yue P, Yang M (2018) Hyaluronic acid based nanocrystals hydrogels for enhanced topical delivery of drug: a case study. Carbohydr Polym 202:64–7110.1016/j.carbpol.2018.08.112 ↗
96. Kumar A, Valamla B, Thakor P, Chary PS, Rajana N, Mehra NK (2022) Development and evaluation of nanocrystals loaded hydrogel for topical application. J Drug Deliv Sci Technol 74:10350310.1016/j.jddst.2022.103503 ↗
97. Wollina U, Tirant M, Vojvodic A, Lotti T (2019) Treatment of psoriasis: novel approaches to topical delivery. Open Access Maced J Med Sci 7:301810.3889/oamjms.2019.414 ↗
98. Kumar M, Shanthi N, Mahato AK, Soni S, Rajnikanth PS (2019) Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity. Heliyon 5:e01688
99. Valamla B, Thakor P, Phuse R, Dalvi M, Kharat P, Kumar A, Panwar D, Singh SB, Giorgia P, Mehra NK (2022) Engineering drug delivery systems to overcome the vaginal mucosal barrier: current understanding and research agenda of mucoadhesive formulations of vaginal delivery. J Drug Deliv Sci Technol 70:10316210.1016/j.jddst.2022.103162 ↗
100. Notario-Pérez F, Cazorla-Luna R, Martín-Illana A, Galante J, Ruiz-Caro R, das Neves J, Veiga M-D (2020) Design, fabrication and characterisation of drug-loaded vaginal films: state-of-the-art. J Control Release 327:477–49910.1016/j.jconrel.2020.08.032 ↗